You just read:

BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC

News provided by

BerGenBio ASA

Nov 02, 2018, 02:16 ET